Investigating the role of specific proteins in head and neck cancer progression
Defining the β-catenin/CBP-catenin/CBP axis in head and neck cancer
This study is looking at how specific proteins are involved in the development of head and neck cancer, especially in people who use tobacco and alcohol, and it aims to find new ways to stop cancer growth and spread, which could help patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10991376 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins, specifically β-catenin and CBP, contribute to the progression of head and neck squamous cell carcinoma (HNSCC), particularly in cases associated with tobacco and alcohol use. By utilizing advanced computational methods alongside genomic and biochemical analyses, the researchers aim to uncover the mechanisms that lead to the transition from non-invasive lesions to advanced cancer. The study also explores the effects of small molecule antagonists on inhibiting cancer cell growth and metastasis, potentially leading to new treatment strategies for patients with this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with head and neck squamous cell carcinoma, particularly those with HPV-negative oral squamous cell carcinoma linked to tobacco and alcohol use.
Not a fit: Patients with head and neck cancers that are HPV-positive or those with other unrelated malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that effectively inhibit the progression of head and neck cancer.
How similar studies have performed: Previous research has shown promising results in targeting β-catenin/CBP signaling pathways in cancer, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Kukuruzinska, Maria a. — Boston University Medical Campus
- Study coordinator: Kukuruzinska, Maria a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.